Inactivation of digoxin by the gut flora: reversal by antibiotic therapy.

No abstract is available for this paper.

• Publication year

  1981

• Venue

  New England Journal of Medicine

• Publication date

  1981-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJM198110013051403PMID 7266632
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Urinary excretion of reduced metabolites of digoxin.

  1981cited by this paper
• Intestinal secretion of digoxin in the rat

  1980cited by this paper
• Influence of gut microflora on bioavailability.

  1979cited by this paper
• Digoxin metabolism in patients.

  1978cited by this paper
• Comparison of the pharmacokinetics of digoxin and dihydrodigoxin in cats in single-dose studies

  1978cited by this paper
• Biochemical pharmacology of the intestinal flora.

  1978cited by this paper
• Correlation between inhibition of (Na+, K+)-membrane-ATPase and positive inotropic activity of cardenolides in isolated papillary muscles of guinea pig

  1978cited by this paper
• Biliary excretion of digoxin in man

  1976cited by this paper
• Fractionation of tritiated digoxin and dihydrodigoxin with DEAE-sephadex LH-20.

  1976cited by this paper
• Absorption of digoxin from the distal parts of the intestine in man

  1975cited by this paper
• The measurement of urinary digoxin and dihydrodigoxin by radioimmunoassay and by mass spectroscopy.

  1975cited by this paper
• Serum digitalis measurements in the assessment of digitalis resistance and sensitivity.

  1975cited by this paper
• The reactivity of derivatives of digoxin and digitoxin as measured by the Na-K-atpase displacement assay and by radioimmunoassay.

  1975cited by this paper
• The reactivity of derivatives of digoxin and digitoxin as measured by the Na-K-atpase displacement assay and by radioimmunoassay.

  1975cited by this paper
• Absorption of digoxin in man after oral and intrasigmoid administration studied by portal vein catheterization

  1975cited by this paper
• Ouabain-receptor interactions in (Na+ plus K+)-ATPase preparations. IV. The molecular structure of different cardioactive steroids and other substances and their affinity to the glycoside receptor.

  1974cited by this paper
• Renal and gastrointestinal excretion of ouabain in dog and man.

  1974cited by this paper
• Digoxin tablet bioavailability: single-dose and steady-state assessment.

  1974cited by this paper
• Correlation of digoxin-tablet dissolution-rate with biological availability.

  1973cited by this paper
• Metabolism of foreign compounds by gastrointestinal microorganisms.

  1973cited by this paper
• The absorption of orally administered (12 - 3 H)digoxin in man.

  1972cited by this paper
• The surface interaction between digoxin and cultured heart cells.

  1972cited by this paper
• Tritiated Digoxin: XIV. Enterohepatic Circulation, Absorption, and Excretion Studies in Human Volunteers

  1970cited by this paper
• Determination of therapeutic and toxic serum digoxin concentrations by radioimmunoassay.

  1969cited by this paper
• Unusually large digitalis requirements. A study of altered digoxin metabolism.

  1968cited by this paper
• STATISTICAL METHODS

  1967cited by this paper
• The difference in velocity between the lethal and inotropic action of dihydrodigoxin

  1964cited by this paper
• Effects of dihydro-ouabain, dihydrodigoxin and dihydrodigitoxin on the heart-lung preparation of the dog.

  1957cited by this paper

• Microbiome-driven PKs: redefining drug metabolism beyond host enzymes

  2026cites this paper
• Exploring the basis of Traditional Chinese Medicine in treating cardiovascular disease: insights into the microbiota-gut-heart axis

  2026cites this paper
• Precision microbiota therapy for IBD: premise and promise

  2025cites this paper
• Impact of Gut Microbiota on Drug Metabolism and Absorption

  2025cites this paper
• Gut-Heart Axis: Microbiome Involvement in Restrictive Cardiomyopathies

  2025cites this paper
• Insights into the Role of Gut Microbiota Modulation in the Management of Various Cardiovascular Diseases: A New Approach for Improving the Efficacy of Current Cardiovascular Medications.

  2025cites this paper
• Credible inferences in microbiome research: ensuring rigour, reproducibility and relevance in the era of AI

  2025cites this paper
• Caught in a bad romance: microbiota increases glyphosate toxicity in the Asian tiger mosquito Aedes albopictus.

  2025cites this paper
• Human xenobiotic metabolism proteins have full-length and split homologs in the gut microbiome

  2025cites this paper
• Digoxin-Induced Gut Dysbiosis: Mechanistic Links to Prostaglandin Dysregulation and Lipid Metabolic Imbalance.

  2025cites this paper
• What Is the Current Status of Research on the Impact of Digitalization in Medicine? A Bibliometric Analysis

  2025cites this paper
• Effect of Probiotics on Immunosuppressive Drug Pharmacokinetics: Interaction between Bacillus subtilis and Tacrolimus in Mice.

  2025cites this paper
• Cardiotonic Steroids as a Potential Novel Approach for Immunomodulation in Inflammatory Bowel Disease

  2025cites this paper
• The Future of Pharmacogenomics: Integrating Epigenetics, Nutrigenomics, and Beyond

  2024cites this paper
• Human xenobiotic metabolism proteins have full-length and split homologs in the gut microbiome

  2024cites this paper
• Gut microbiome and inflammation in cardiovascular drug response: trends in therapeutic success and commercial focus

  2024cites this paper
• Trends in Digitalization and Cultural Identity: A Bibliometric Study on Local Traditions in the Digital Era

  2024cites this paper
• Integrating the gut microbiome and pharmacology

  2024cites this paper
• Microbial metabolism marvels: a comprehensive review of microbial drug transformation capabilities

  2024cites this paper
• Pharma[e]cology: How the Gut Microbiome Contributes to Variations in Drug Response

  2024cites this paper
• Intestinal microbiota, probiotics and their interactions with drugs: knowledge, attitudes and practices of health science students in Serbia

  2024cites this paper
• CRISPR-Cas9 as a gene editing tool using cardiac glycoside reductase operon for digoxin metabolism

  2024cites this paper
• Interactions Between Antidepressants and Intestinal Microbiota

  2023cites this paper
• The Dysbiosis Triggered by First-Line Tuberculosis Antibiotics Fails to Reduce Their Bioavailability

  2023cites this paper
• It's all relative: analyzing microbiome compositions, its significance, pathogenesis and microbiota derived biofilms: Challenges and opportunities for disease intervention

  2023cites this paper
• A toxic shrub turned therapeutic: The dichotomy of Nerium oleander bioactivities.

  2023cites this paper
• Association analysis of gut microbiota and efficacy of SSRIs antidepressants in patients with major depressive disorder.

  2023cites this paper
• Exploring the potential impact of probiotic use on drug metabolism and efficacy.

  2023cites this paper
• The changes of gut microbiota and metabolites in different drug-induced liver injuries.

  2023cites this paper
• Interaction of drugs with gut microbiota modulators

  2023cites this paper
• The Implication of the Gut Microbiome in Heart Failure

  2023cites this paper
• Principles and Terminology for Host–Microbiome–Drug Interactions

  2023cites this paper
• Predicting drug-drug adverse reactions via multi-view graph contrastive representation model

  2023cites this paper
• Drug-gut Microbiome Interaction in Atherosclerosis Therapeutics.

  2023cites this paper
• Dissecting the human gut microbiome to better decipher drug liability: A once-forgotten organ takes center stage

  2023cites this paper
• Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment Microbiome in Cancer Therapy.

  2022cites this paper
• Microbiome epidemiology and association studies in human health

  2022cites this paper
• Mechanisms, therapeutic implications, and methodological challenges of gut microbiota and cardiovascular diseases: a position paper by the ESC Working Group on Coronary Pathophysiology and Microcirculation

  2022cites this paper
• Interplays between drugs and the gut microbiome

  2022cites this paper
• Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism

  2022cites this paper
• How Brain Infarction Links With the Microbiota–Gut–Brain Axis: Hints From Studies Focusing on the Risk Factors for Ischemic Stroke

  2022cites this paper
• Tutorial: Microbiome studies in drug metabolism

  2022cites this paper
• Multimodal interactions of drugs, natural compounds and pollutants with the gut microbiota

  2022cites this paper
• Selective Isolation of Eggerthella lenta from Human Faeces and Characterisation of the Species Prophage Diversity

  2022cites this paper
• Comprehensive Gut Microbiota and Drug Processing

  2021cites this paper
• Can manipulation of gut microbiota really be transformed into an intervention strategy for cardiovascular disease management?

  2021cites this paper
• Tributyltin exposure leads to increased adiposity and reduced abundance of leptogenic bacteria in the zebrafish intestine

  2021cites this paper
• Gut microbiota as a target to limit toxic effects of traditional Chinese medicine: Implications for therapy.

  2021cites this paper
• Gut microbiota metabolism and the permeability of natural products contained in infusions from herb of European goldenrod Solidago virgaurea L.

  2021cites this paper
• Exploring Drug Metabolism by the Gut Microbiota: Modes of Metabolism and Experimental Approaches

  2021cites this paper
• The intestinal 3M (microbiota, metabolism, metabolome) Zeitgeist - from fundamentals to future challenges.

  2021cites this paper
• Contribution of the Gut Microbiome to Drug Disposition, Pharmacokinetic and Pharmacodynamic Variability

  2021cites this paper
• Towards a mechanistic understanding of reciprocal drug–microbiome interactions

  2021cites this paper
• Role of the gut microbiome in cardiovascular drug response: The potential for clinical application

  2021cites this paper
• Gut microbiota and host Cyp450s co-contribute to pharmacokinetic variability in mice with non-alcoholic steatohepatitis: Effects vary from drug to drug

  2021cites this paper
• Understanding the physiological functions of the host xenobiotic-sensing nuclear receptors PXR and CAR on the gut microbiome using genetically modified mice

  2021cites this paper
• The Gut Microbiome and Xenobiotics: Identifying Knowledge Gaps.

  2020cites this paper
• Gut Microbiome in Microbial Pathogenicity

  2020cites this paper
• A comprehensive review of the strategies to improve oral drug absorption with special emphasis on the cellular and molecular mechanisms

  2020cites this paper
• The pharmaco-toxicological conundrum of oleander: Potential role of gut microbiome.

  2020cites this paper
• Targeting gut microbiota for precision medicine: Focusing on the efficacy and toxicity of drugs

  2020cites this paper
• Disruption of the gut microbiota attenuates epithelial ovarian cancer sensitivity to cisplatin therapy

  2020cites this paper
• The influence of the gut microbiota on the bioavailability of oral drugs

  2020cites this paper
• Potential Implications of Gut Microbiota in Drug Pharmacokinetics and Bioavailability

  2020cites this paper
• Understanding the Physiological Functions of the Host Xenobiotic-sensing Nuclear Receptors PXR and CAR on the Gut Microbiome using Genetically Modi�ed Mice

  2020cites this paper
• Review article: how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease

  2020cites this paper
• The Progress of Multi-Omics Technologies: Determining Function in Lactic Acid Bacteria Using a Systems Level Approach

  2020cites this paper
• The metabolic effect of gut microbiota on drugs

  2020cites this paper
• Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response

  2020cites this paper
• Metagenomic Systems Biology: Integrative Analysis of the Microbiome

  2020cites this paper
• The gut microbiome in solid organ transplantation

  2020cites this paper
• Gut microbiota in reductive drug metabolism.

  2020cites this paper
• Role of microbes, metabolites and effector compounds in host–microbiota interaction: a pharmacological outlook

  2019cites this paper
• Gut microbiota, a new frontier to understand traditional Chinese medicines

  2019cites this paper
• The Gut Microbiome and Response to Cardiovascular Drugs.

  2019cites this paper
• Microbes, Their Metabolites, and Effector Molecules: A Pharmacological Perspective for Host-Microbiota Interaction

  2019cites this paper
• Pharmaceuticals from Microbes: The Bioengineering Perspective

  2019cites this paper
• Mechanisms of gastrointestinal microflora on drug metabolism in clinical practice

  2019cites this paper
• The Role of the Human Microbiome in Chemical Toxicity

  2019cites this paper
• Bringing microbiome-drug interaction research into the clinic

  2019cites this paper
• The human gut chemical landscape predicts microbe-mediated biotransformation of foods and drugs

  2019cites this paper
• Gut microbiota: what is its place in pharmacology?

  2019cites this paper
• Interplay Between the Host, the Human Microbiome, and Drug Metabolism

  2019cites this paper
• Insights from pharmacokinetic models of host-microbiome drug metabolism

  2019cites this paper
• The gut microbiome: an orchestrator of xenobiotic metabolism

  2019cites this paper
• Effects of Gut Microbiota on Drug Metabolism and Guidance for Rational Drug Use Under Hypoxic Conditions at High Altitudes.

  2019cites this paper
• Role of Gut Microbiota in the Pharmacological Effects of Natural Products

  2019cites this paper
• Advancing functional and translational microbiome research using meta-omics approaches

  2019cites this paper
• Precarious Symbiosis Between Host and Microbiome in Cardiovascular Health

  2019cites this paper
• Chemistry and Enzymology Encoded by the Human Microbiome

  2019cites this paper
• Gut Microbiota in Phytopharmacology: A Comprehensive Overview Of Concepts, Reciprocal Interactions, Biotransformations And Mode Of Actions.

  2019cites this paper
• Understanding the Physiological Functions of the Host Xenobiotic-sensing Nuclear Receptors PXR and CAR on the Gut Microbiome using Genetically-modified Mice

  2019cites this paper
• How to Determine the Role of the Microbiome in Drug Disposition

  2018cites this paper
• Gut microbiota modulates drug pharmacokinetics

  2018cites this paper
• Understanding mucosal and microbial functionality of the female reproductive tract by metaproteomics: Implications for HIV transmission

  2018cites this paper
• Effects of medicines used to treat gastrointestinal diseases on the pharmacokinetics of coadministered drugs: a PEARRL Review

  2018cites this paper
• Pharmacological Activation of PXR and CAR Downregulates Distinct Bile Acid-Metabolizing Intestinal Bacteria and Alters Bile Acid Homeostasis

  2018cites this paper
• Discovery and characterization of a prevalent human gut bacterial enzyme sufficient for the inactivation of a family of plant toxins

  2018cites this paper
• Pharmacomicrobiomics: a novel route towards personalized medicine?

  2018cites this paper
• Therapeutic implications of the gastrointestinal microbiome.

  2018cites this paper